Supernus Pharmaceuticals, Inc. (SUPN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.52B
Last updated: Nov 17, 2026 at 11:06 AM ET
Supernus Pharmaceuticals, Inc. (SUPN) Financials: Revenue, Profit and Cash Flow
Supernus Pharmaceuticals reported revenue of $718.95M for the fiscal year ended Dec 31, 2025, up 8.6% from the year before. That year, net income was -$38.55M with a net margin of -5.4%, operating cash flow was $47.33M and free cash flow was $45.99M. The quarter ended Jun 30, 2026 had revenue of $219.06M and net income of -$58.37M.
Revenue and Margins
The operating margin was -8.7% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $425.08M, a compound annual rate of 6.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $718.95M | +8.6% | 89.6% | -8.7% | -5.4% |
| Dec 2024 | $661.82M | +8.9% | 88.2% | 12.3% | 11.2% |
| Dec 2023 | $607.52M | -8.9% | 86.2% | -0.9% | 0.2% |
| Dec 2022 | $667.24M | +15.1% | 86.9% | 6.9% | 9.1% |
| Dec 2021 | $579.77M | +11.4% | 87.1% | 14.8% | 9.2% |
| Dec 2020 | $520.40M | +32.5% | 89.9% | 33.4% | 24.4% |
| Dec 2019 | $392.75M | -3.9% | 95.8% | 37.8% | 28.8% |
| Dec 2018 | $408.90M | +35.3% | 96.2% | 35.3% | 27.1% |
| Dec 2017 | $302.24M | -28.9% | 95.0% | 32.9% | 19.0% |
| Dec 2016 | $425.08M | N/A | 97.2% | 12.8% | 21.5% |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Jun 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $718.95M | $661.82M | $607.52M | $667.24M | $579.77M | $520.40M | $392.75M | $408.90M | $302.24M | $425.08M |
| Cost of revenue | $74.56M | $77.91M | $83.78M | $87.22M | $75.06M | $52.46M | $16.66M | $15.36M | $15.21M | $11.99M |
| Gross profit | $644.39M | $583.91M | $523.74M | $580.02M | $504.71M | $467.94M | $376.10M | $393.54M | $287.02M | $413.10M |
| Research and development | $106.23M | $108.80M | $91.59M | $74.55M | $90.47M | $75.96M | $69.10M | $89.21M | $49.58M | $42.79M |
| Operating income | -$62.28M | $81.67M | -$5.27M | $46.12M | $86.03M | $173.70M | $148.57M | $144.44M | $99.54M | $54.22M |
| Net income | -$38.55M | $73.86M | $1.32M | $60.71M | $53.42M | $126.95M | $113.06M | $110.99M | $57.28M | $91.22M |
| EBITDA | $41.00M | $180.11M | $90.45M | $158.70M | $123.69M | $200.48M | $165.82M | $157.42M | $108.24M | $57.58M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $219.06M | $207.71M | $211.57M | $192.10M | $165.45M | $149.82M | $174.16M | $175.69M | $168.32M | $143.64M | $164.31M | $153.88M |
| Gross profit | $185.39M | $184.31M | $188.56M | $173.14M | $148.63M | $134.06M | $148.06M | $158.11M | $150.41M | $127.33M | $144.69M | $134.28M |
| Operating income | -$57.96M | -$8.33M | -$3.94M | -$60.23M | $12.14M | -$10.26M | $21.41M | $40.84M | $22.57M | -$3.15M | -$996.00K | $8.14M |
| Net income | -$58.37M | -$2.29M | -$4.11M | -$45.12M | $22.50M | -$11.83M | $15.33M | $38.50M | $19.92M | $124.00K | $1.18M | -$15.98M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $31.05M by $97.40M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.45B | $1.37B | $1.28B | $1.70B | $1.69B | $1.50B | $1.16B | $977.81M | $424.46M | $309.57M |
| Current assets | $644.18M | $686.07M | $493.11M | $734.15M | $601.59M | $630.42M | $472.64M | $493.49M | $228.45M | $151.40M |
| Cash and equivalents | $128.45M | $69.33M | $75.05M | $93.12M | $203.43M | $288.64M | $181.38M | $192.25M | $100.30M | $66.40M |
| Total liabilities | $390.93M | $332.34M | $356.16M | $816.30M | $873.30M | $759.24M | $564.85M | $524.79M | $156.98M | $117.81M |
| Short-term debt | $31.05M | $47.34M | $52.07M | $423.09M | $44.84M | $30.90M | $0 | $2.18M | $4.28M | $69.38M |
| Long-term debt | N/A | N/A | N/A | N/A | $379.25M | $361.75M | $345.17M | $329.46M | $0 | $4.17M |
| Shareholder equity | $1.06B | $1.04B | $921.52M | $886.20M | $815.85M | $744.86M | $595.43M | $453.02M | $267.48M | $191.75M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.43B | $1.50B | $1.45B | $1.42B | $1.38B | $1.35B | $1.37B | $1.34B | $1.32B | $1.30B | $1.28B | $1.29B |
| Total liabilities | $396.88M | $423.92M | $390.93M | $370.09M | $318.50M | $316.58M | $332.34M | $335.55M | $358.38M | $374.92M | $356.16M | $372.97M |
| Cash and equivalents | $179.95M | $184.87M | $128.45M | $151.37M | $144.71M | $115.85M | $69.33M | $31.67M | $52.09M | $63.40M | $75.05M | $94.98M |
| Shareholder equity | $1.03B | $1.08B | $1.06B | $1.05B | $1.06B | $1.03B | $1.04B | $1.01B | $957.45M | $929.17M | $921.52M | $912.19M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 97.2% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $47.33M | $171.95M | $111.08M | $116.83M | $127.13M | $138.40M | $143.13M | $128.99M | $114.64M | $66.81M |
| Capital expenditures | $1.34M | $725.00K | $551.00K | $412.00K | $2.04M | $3.69M | $1.39M | $844.00K | $2.03M | $1.60M |
| Free cash flow | $45.99M | $171.23M | $110.53M | $116.41M | $125.08M | $134.71M | $141.74M | $128.14M | $112.61M | $65.21M |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $10.44M | $0 | N/A |
| Investing cash flow | $4.11M | -$189.87M | $268.73M | -$216.66M | -$81.91M | -$34.70M | -$157.92M | -$413.48M | -$86.42M | -$35.96M |
| Financing cash flow | $9.13M | $12.19M | -$397.88M | -$10.48M | -$130.42M | $3.56M | $3.93M | $376.44M | $5.68M | $2.05M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.81M | $66.52M | $19.86M | -$61.66M | $58.53M | $30.60M | $44.41M | $53.52M | $35.62M | $38.40M | $44.96M | $35.88M |
| Capital expenditures | $568.00K | $0 | $427.00K | $129.00K | $455.00K | $327.00K | $213.00K | $200.00K | $64.00K | $248.00K | $36.00K | $150.00K |
| Free cash flow | -$5.38M | $66.52M | $19.43M | -$61.79M | $58.08M | $30.27M | $44.19M | $53.32M | $35.56M | $38.15M | $44.92M | $35.73M |
Frequently Asked Questions About SUPN
What is Supernus Pharmaceuticals' annual revenue?
Supernus Pharmaceuticals reported revenue of $718.95M for the fiscal year ended Dec 31, 2025.
How fast is Supernus Pharmaceuticals' revenue growing?
Revenue was up 8.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.5%.
Is Supernus Pharmaceuticals profitable?
No. Supernus Pharmaceuticals reported net income of -$38.55M for the fiscal year ended Dec 31, 2025, with a net margin of -5.4%.
How much free cash flow does SUPN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $47.33M minus capital expenditures of $1.34M produced free cash flow of $45.99M.
How much debt does Supernus Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $31.05M and cash and equivalents of $128.45M.
SUPN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors